View Clinical Trial (Medical Research Study)
Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)
| City: |
|
Rochester |
| State: |
|
Minnesota |
| Zip Code: |
|
55905 |
| Conditions: |
|
Brain and Central Nervous System Tumors |
| Purpose: |
|
RATIONALE: The measles virus, that has been changed in a certain way, may kill tumor cells
without damaging normal cells.
PURPOSE: This phase I trial is studying the side effects and best dose of viral therapy in
treating patients with recurrent glioblastoma multiforme.
|
| Study Summary: |
|
OBJECTIVES:
Primary
- Determine the safety and toxicity of intratumoral and/or resection cavity
administration of a recombinant, attenuated Edmonston B vaccine strain derivative of
measles virus genetically engineered to produce human carcinoembryonic antigen (CEA) in
patients with recurrent glioblastoma multiforme.
- Determine the maximum tolerated dose of this oncolytic virus in these patients.
- Determine viral gene expression at each dose level as manifested by CEA titers in
patients treated with this oncolytic virus.
- Assess viremia, viral replication, and measles virus shedding/persistence after
intratumoral administration of this oncolytic virus.
- Assess humoral and cellular immune response to the injected virus in these patients.
Secondary
- Determine, preliminarily, the antitumor efficacy of this vaccine in these patients.
OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 sequential
treatment groups.
- Group 1 (resection cavity administration): Patients undergo en block resection of their
tumor (after confirming diagnosis) on day 1, followed by recombinant measles virus
encoding human carcinoembryonic antigen (MV-CEA) administered into the resection cavity
over 10 minutes.
- Group 2 (intratumoral and resection cavity administration): Patients undergo placement
of a catheter within the tumor, followed by MV-CEA administration into the tumor
through the catheter over 10 minutes on day 1. Patients undergo en block resection of
their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA
administered around the tumor bed.
In both groups, cohorts of 1-6 patients receive escalating doses of MV-CEA until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2
of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD in group 1 has been
determined, patients are assigned to group 2. The MTD in group 1 is used to determine the
starting dose in group 2. At least 10 patients are treated at the MTD determined in group 2.
Biopsy specimen, resected tumor, normal tissue, and peripheral blood are collected during
study for immunologic and biomarker correlative studies, including analysis of CD46 receptor
levels (by immunohistochemistry [IHC]), measles virus N protein (by IHC), measles and viral
gene expression and replication (by in situ hybridization), CEA monitoring (by immunoassay),
measles virus N mRNA (by reverse transcriptase-polymerase chain reaction), and measles virus
immunity. Assessments of immune competence and peripheral response to viral administration
are also performed.
After completion of study treatment, patients are followed periodically for up to 15 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed grade 4 astrocytoma (glioblastoma multiforme) at primary
diagnosis and/or recurrence
- Recurrent disease
- Candidate for gross total or subtotal resection
- No expected communication between ventricles and resection cavity as a result of
surgery
- Antimeasles virus immunity as demonstrated by IgG antimeasles antibody levels of ≥ 20
EU/mL as determined by enzyme immunoassay
- Human carcinoembryonic antigen (CEA) < 3 ng/mL
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST ≤ 2 times ULN
- Creatinine ≤ 2.0 times ULN
- Hemoglobin ≥ 9.0 g/dL
- PT and aPTT ≤ 1.3 times ULN
- Willing to provide biological specimens as required by the study
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infection within the past 5 days
- No history of tuberculosis or purified protein derivative positivity
- No New York Heart Association class III or IV cardiac disease
- Adequate seizure control
- HIV negative
- No history of other immunodeficiency
- No history of chronic hepatitis B or C
- No exposure (household contacts) to children ≤ 15 months of age or to people with
known immunodeficiency
- No allergy to measles vaccine or history of severe reaction to prior measles
vaccination
- No requirement for blood product support
PRIOR CONCURRENT THERAPY:
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea-based
chemotherapy) and recovered
- More than 4 weeks since prior immunotherapy
- More than 4 weeks since prior biologic therapy
- More than 2 weeks since prior noncytotoxic antitumor drugs (i.e., small molecule cell
cycle inhibitors)
- More than 6 weeks since prior radiotherapy
- No prior viral or gene therapy
- No history of organ transplantation
- No concurrent chemotherapy, other immunotherapy, radiotherapy, or any other ancillary
therapy considered investigational (utilized for a non-FDA-approved indication and in
the context of a research investigation)
- No concurrent enrollment on any other study involving a pharmacologic agent (e.g.,
drugs, biologics), immunotherapy approaches, or gene therapy whether for symptom
control or therapeutic intent
|
| NCT ID: |
|
NCT00390299 |
| Primary Contact: |
|
Study Chair
Evanthia Galanis, MD
Mayo Clinic
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Rochester, Minnesota 55905
United States
Clinical Trials Office - All Mayo Clinic Locations
Phone: 507-538-7623
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|